InSphero today announced that the company is making their 3D in vitro products available to researchers in the European Union market more easily by signing a distribution agreement with Darwin Microfluidics, an innovative startup dedicated to bringing advanced microfluidic solutions to researchers worldwide.
InSphero, a global pioneer in 3D cell culture and organ-on-chip technology, is well known for its 3D in vitro products, from Akura Plate Technology to Akura MPS systems. Simplified aggregation and handling of spheroids in SBS standard Akura Plates facilitates transfer and integration of 3D models in micro-physiological systems by automated liquid-handling systems.
“I am looking forward to working with the scientists of Darwin Microfluidics to expand our range of applications for researchers in the microfluidics field, said Paul Clémençon, Head of Business Development of InSphero.” Combining our scalable, reliable, and automation-compatible Akura Plate Formats with microfluidic applications helps scientists to address current challenges in drug development.
With a passion for microfluidics, Darwin Microfluidics aims to enable research laboratories and members of the scientific community to access the best available instruments and accessories in the market.
“Darwin Microfluidics offers a deep expertise in biotechnology, microfluidics, lab-on-a-chip and organ-on-chip technology. We are experienced in business development of innovative products, and we are thrilled to offer InSphero’s Akura Plate and OoC Technology to our scientific community,” said Vincent Rocher, CEO of Darwin Microfluidics.
Priority medicines (PRIME) is a scheme run by the European Medicines Agency (EMA) to enhance support for the development of medicines that target an unmet medical need. The scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimize development plans and speed up evaluation so these medicines can reach patients earlier EMA CHMP acknowledges that n
LubioScience GmbH, Switzerland’s leading Life Sciences platform, expands its product portfolio with the addition of fresh human blood products and biospecimens provided by Research Donors from the UK.
Preliminary data from 472 nine-month-old infants confirm favorable safety and tolerability profile and demonstrate significant immunogenicity for the four most common pathogen serotypes Results support further development with LimmaTech expecting to initiate the next clinical trial in 2024 Topline results from the completed Phase I/II will be reported in the first half of 2024
InterAx Biotech AG, a product development company pioneering computational pharmacology for drug discovery, announces that the company's most advanced artificial intelligence platform has uncovered novel cellular signaling modes of action which enable InterAx to design efficacious orally available drugs for diabetes, obesity, and immuno oncology. Particularly promising results are coming from the
Its proprietary innovative polymer technology reduces bacterial bioburden without triggering antimicrobial resistance, one of the top global public health threats The Advanced Wound Dressing (AWD) market is valued at 4.5 billion USD and is witnessing increasing demand and technological advancements The company is looking to expand development and commercial collaborations with industry leaders
Vandria is advancing a portfolio of mitophagy inducers to address age-related chronic diseases of the CNS, muscle, lung and liver Innosuisse grant totalling CHF 2.5M (€ 2.7M) to support early clinical development plan for lead CNS mitophagy drug candidate VNA-318 that has the potential to treat cognitive impairment, dementia, Alzheimer’s and Parkinson’s Disease Eurostars grant totalling €1